Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

Author:

Mellqvist Ulf-Henrik1,Gimsing Peter2,Hjertner Oyvind3,Lenhoff Stig4,Laane Edward5,Remes Kari6,Steingrimsdottir Hlif7,Abildgaard Niels8,Ahlberg Lucia9,Blimark Cecilie1,Dahl Inger Marie10,Forsberg Karin11,Gedde-Dahl Tobias12,Gregersen Henrik13,Gruber Astrid14,Guldbrandsen Nina12,Haukås Einar15,Carlson Kristina16,Kvam Ann Kristin12,Nahi Hareth17,Lindås Roald18,Andersen Niels Frost19,Turesson Ingemar20,Waage Anders3,Westin Jan1

Affiliation:

1. Department of Medicine, Section of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden;

2. Rigshospitalet and University of Copenhagen, Copenhagen, Denmark;

3. Avdelning for blodsykdommer, St. Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway;

4. Department of Hematology, Skane University Hospital, Lund, Sweden;

5. North Estonian Regional Hospital, Tallinn, Estonia;

6. Department of Medicine, Turku University Central Hospital, Turku, Finland;

7. Landspitali University Hospital, Reykjavik, Iceland;

8. Department of Hematology, Odense University Hospital, Odense, Denmark;

9. Department of Hematology, Linkoping University Hospital, Linkoping, Sweden;

10. University North Norway, Tromso, Norway;

11. Norrlands University Hospital, Umea, Sweden;

12. Oslo University Hospital, Oslo, Norway;

13. Aalborg Sygehus, Aalborg, Denmark;

14. Center of Hematology, Karolinska Institute, Stockholm, Sweden;

15. Stavanger University Hospital, Stavanger, Norway;

16. Akademiska University Hospital, Uppsala, Sweden;

17. Karolinska Institutet/Karolinska University Hospital Huddinge, Stockholm, Sweden;

18. Haukeland Hospital, Bergen, Norway;

19. Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; and

20. Department of Hematology and Coagulation, Skane University Hospital, Malmo, Sweden

Abstract

Key Points Bortezomib consolidation after ASCT improves PFS in myeloma. Improvement of response is seen with bortezomib consolidation after ASCT in myeloma.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference31 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3